A novel BAD phosphorylation inhibitor combined with EGFR tyrosine kinase inhibitors in EGFR-mutant lung adenocarcinoma treatment. (October 2022) - Zhang, X.; Shu, C.; Huang, P.; Pandey, V.; Lobie, P.E.